CIMA LABS Announces That Akzo Nobel And Organon Inc. Have Filed Patent Infringement Suit Against Barr Laboratories.Business Editors EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--May 3, 2002 CIMA LABS INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . (Nasdaq:CIMA) today announced that Akzo Nobel NV (Nasdaq:AKZOY) and its Organon or·ga·non or or·ga·num n. pl. or·ga·nons or or·ga·nums or or·ga·na 1. An organ. 2. A set of principles for use in scientific investigation. organon pl. organa [Gr.] organ. Inc. pharmaceutical unit filed suit in the Federal District Court of Newark, N.J., today against Barr Laboratories, Inc. (NYSE NYSE See: New York Stock Exchange :BRL BRL In currencies, this is the abbreviation for the Brazilian Real. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. ), claiming that Barr has infringed on the patent covering the use of Remeron(R) SolTab(TM) (mirtazapine) orally disintegrating tablets in combination with one or more SSRI's for the treatment of depression. Barr previously informed Organon that it has filed a Paragraph IV Abbreviated New Drug Application abbreviated new drug application Pharmacology An application made in the US by a pharmaceutical company requesting authority to market a 'new' drug for which both its therapeutic indications and formulation were previously approved by the FDA in another similar or ANDA ANDA abbr. abbreviated new drug application with the Food and Drug Administration for a generic version of mirtazapine in an orally disintegrating or fast dissolve tablet formulation. CIMA developed and manufactures Remeron SolTab for Organon. About CIMA LABS CIMA develops and manufactures prescription and over-the-counter products based upon its proprietary, fast-dissolve drug delivery technologies, OraSolv(R) and DuraSolv(R). Based on our technologies, an active drug ingredient, which we frequently taste-mask, is formulated into a new, orally disintegrating dosage form that dissolves quickly in the mouth without chewing or the need for water. CIMA's business involves a dual operating strategy. We develop and manufacture fast-dissolve versions of drugs for pharmaceutical company partners for whom we currently produce three branded prescription pharmaceuticals and two over-the-counter brands. CIMA is also developing proprietary products utilizing our fast-dissolve technologies, as well as our new OraVescent(R) enhanced absorption, transmucosal drug delivery system. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion